| Literature DB >> 28819022 |
Mark J Bucsek1, Guanxi Qiao1, Cameron R MacDonald1, Thejaswini Giridharan1, Lauren Evans1, Brian Niedzwecki1, Haichao Liu1, Kathleen M Kokolus1, Jason W-L Eng1, Michelle N Messmer1, Kristopher Attwood2, Scott I Abrams1, Bonnie L Hylander1, Elizabeth A Repasky3.
Abstract
The immune context of tumors has significant prognostic value and is predictive of responsiveness to several forms of therapy, including immunotherapy. We report here that CD8+ T-cell frequency and functional orientation within the tumor microenvironment is regulated by β2-adrenergic receptor (β-AR) signaling in host immune cells. We used three strategies-physiologic (manipulation of ambient thermal environment), pharmacologic (β-blockers), and genetic (β2-AR knockout mice) to reduce adrenergic stress signaling in two widely studied preclinical mouse tumor models. Reducing β-AR signaling facilitated conversion of tumors to an immunologically active tumor microenvironment with increased intratumoral frequency of CD8+ T cells with an effector phenotype and decreased expression of programmed death receptor-1 (PD-1), in addition to an elevated effector CD8+ T-cell to CD4+ regulatory T-cell ratio (IFNγ+CD8+:Treg). Moreover, this conversion significantly increased the efficacy of anti-PD-1 checkpoint blockade. These data highlight the potential of adrenergic stress and norepinephrine-driven β-AR signaling to regulate the immune status of the tumor microenvironment and support the strategic use of clinically available β-blockers in patients to improve responses to immunotherapy. Cancer Res; 77(20); 5639-51. ©2017 AACR. ©2017 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28819022 PMCID: PMC5645237 DOI: 10.1158/0008-5472.CAN-17-0546
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701